Uses of Jilazo 100mg/ml Injection
Jilazo 100mg/ml Injection is used for the treatment or prevention of the following disease(s):
Iron Deficiency
Side effects of Jilazo 100mg/ml Injection
The most common side effects of Jilazo 100mg/ml Injection are - Nausea, Constipation, Pain, Fever, Diarrhea, Abdominal Cramp, Vomiting, Fever
These side effects can usually occur in patients. However, these are only indicative and not all patients will experience them.
Precautions while taking Jilazo 100mg/ml Injection
Do not use Jilazo 100mg/ml Injection if you are allergic to - Iron Isomaltoside
If you have heart disease, liver or kidney disease, drug or alcohol addiction, consult your doctor before using Jilazo 100mg/ml Injection.
If you are allergic to any medicine or food, consult your doctor before using this medicine.
Use this medicine under the supervision of your doctor.
To avoid an adverse reaction, consult your doctor if you are already taking other medicines.
Dosage of Jilazo 100mg/ml Injection
Jilazo 100mg/ml Injection contains - Iron Isomaltoside
Iron plays an essential element for blood production.
Overdose of Jilazo 100mg/ml Injection
The dosage of Jilazo 100mg/ml Injection depends on many factors such as the patient age, health, medical condition or history of the patient and many other conditions.
Please use this medicine as prescribed by your doctor.
Onset of Action of Jilazo 100mg/ml Injection
If you forget to take a dose of Jilazo 100mg/ml Injection, do not take two doses at the same time, there is a risk of overdose.
If you notice any unusual reaction in your body after taking this medicine, contact your doctor immediately or call your local medical emergency number.
Duration of Action of Jilazo 100mg/ml Injection
Precautions & Warnings
Alcohol
Information will be added soon.
Pregnancy
Information will be added soon.
Breastfeeding
Information will be added soon.
Driving
Information will be added soon.
Kidney
Information will be added soon.
Liver
Information will be added soon.
Interactions
Information will be added soon.